United States · FDA National Drug Code directory
OGIVRI
A source-listed medicine record.
Factual source checks only. This page is not a clinically reviewed monograph. Historical or discontinued records may be included; listing does not confirm approval, current availability or pharmacy stock.
Medicine identity
- Source reference
- 67457-991_b57e61b9-04b7-4d8b-b7c2-be56a060421b
- Product NDC
- 67457-991
- Form
- INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION
- Composition / generic term
- trastuzumab
- Labeler
- Mylan Institutional LLC
- Marketing category
- BLA
- Marketing start / end (source format)
- 20191129 / 20270228
Source-listed ingredients
- TRASTUZUMAB — 150 mg/7.4mL
These values do not establish equivalence or a dose recommendation.
Packages
- 1 VIAL in 1 CARTON (67457-991-15) / 15 mL in 1 VIAL · 67457-991-15
Source and coverage
Open FDA National Drug Code directory →
Snapshot retrieved: 2026-09-17. This is the acquisition date, not a medical review date.
Clinical information, images and comparisons appear only when separately reviewed for this record. Coverage may be incomplete. Ask a pharmacist or clinician about your treatment.
Browse United States records →